Article | October 4, 2021

New Therapies Require A New Approach To Regulatory Interactions — A Discussion With bluebird bio's Scott Cleve

Source: Cytiva

By Cytiva


In biopharma, change is the name of the game, with high-stakes competition, fast-paced scientific discovery, shifting business models, and new molecular entities. Global regulators can expect to overcome challenges when reacting and responding to the numerous ways the industry has evolved over the years.

Scott Cleve, currently Vice President of Regulatory Operations and Compliance at bluebird bio, has witnessed this evolution firsthand throughout more than 20 years in regulatory operations with Accenture, AbbVie, Astellas, and Boehringer Ingelheim. bluebird bio is the maker of a fifth-line multiple myeloma therapy that received FDA approval in March.

Cleve recently sat down with BioProcess Online to talk about today’s regulatory paradigm and what biopharma should remember when engaging with regulators.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.

Subscribe to Pharmaceutical Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Pharmaceutical Online